| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcus agalactiae | 44 | 2013 | 79 | 5.290 |
Why?
|
| Communicable Diseases, Emerging | 13 | 2019 | 22 | 3.680 |
Why?
|
| Disease Outbreaks | 28 | 2022 | 103 | 3.650 |
Why?
|
| Population Surveillance | 13 | 2024 | 208 | 2.890 |
Why?
|
| Streptococcal Infections | 29 | 2013 | 76 | 2.710 |
Why?
|
| Antigens, Surface | 20 | 2009 | 188 | 2.480 |
Why?
|
| Bacterial Proteins | 27 | 2013 | 732 | 2.210 |
Why?
|
| Internet | 10 | 2016 | 454 | 1.980 |
Why?
|
| Global Health | 13 | 2021 | 158 | 1.760 |
Why?
|
| Influenza, Human | 7 | 2024 | 186 | 1.470 |
Why?
|
| Epidemiological Monitoring | 7 | 2020 | 25 | 1.350 |
Why?
|
| Antigens, Bacterial | 13 | 2008 | 211 | 1.190 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2014 | 88 | 1.180 |
Why?
|
| Electronic Mail | 4 | 2017 | 45 | 1.100 |
Why?
|
| Pandemics | 7 | 2024 | 605 | 0.930 |
Why?
|
| Epidemics | 4 | 2019 | 22 | 0.920 |
Why?
|
| Communicable Disease Control | 3 | 2019 | 37 | 0.910 |
Why?
|
| Public Health | 9 | 2024 | 177 | 0.870 |
Why?
|
| Vaccines | 3 | 2016 | 96 | 0.850 |
Why?
|
| Glycosaminoglycans | 3 | 2008 | 18 | 0.830 |
Why?
|
| Foodborne Diseases | 2 | 2020 | 5 | 0.770 |
Why?
|
| Humans | 99 | 2024 | 58815 | 0.750 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 7 | 2003 | 76 | 0.740 |
Why?
|
| Vaccination | 7 | 2021 | 331 | 0.720 |
Why?
|
| Streptococcal Vaccines | 5 | 2008 | 5 | 0.640 |
Why?
|
| Communicable Diseases | 6 | 2017 | 76 | 0.640 |
Why?
|
| Massachusetts | 15 | 2024 | 2093 | 0.620 |
Why?
|
| Sentinel Surveillance | 4 | 2023 | 20 | 0.610 |
Why?
|
| Public Opinion | 3 | 2020 | 22 | 0.610 |
Why?
|
| Epithelial Cells | 7 | 2008 | 372 | 0.610 |
Why?
|
| Antibodies, Bacterial | 13 | 2008 | 192 | 0.600 |
Why?
|
| Information Services | 2 | 2006 | 35 | 0.530 |
Why?
|
| Plant Diseases | 2 | 2014 | 11 | 0.530 |
Why?
|
| Immunization | 6 | 2016 | 127 | 0.510 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 189 | 0.500 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2014 | 2 | 0.490 |
Why?
|
| Animals | 38 | 2021 | 19393 | 0.460 |
Why?
|
| Epidemiologic Methods | 1 | 2013 | 68 | 0.430 |
Why?
|
| Respiratory Tract Infections | 2 | 2024 | 81 | 0.430 |
Why?
|
| Health Status Disparities | 1 | 2013 | 147 | 0.400 |
Why?
|
| Intensive Care Units | 2 | 2020 | 439 | 0.400 |
Why?
|
| Information Storage and Retrieval | 2 | 2009 | 79 | 0.390 |
Why?
|
| Polysaccharides, Bacterial | 6 | 2006 | 42 | 0.390 |
Why?
|
| Public Health Informatics | 1 | 2011 | 7 | 0.390 |
Why?
|
| Genome, Viral | 3 | 2021 | 119 | 0.380 |
Why?
|
| Electronic Health Records | 3 | 2024 | 346 | 0.370 |
Why?
|
| Dengue | 1 | 2011 | 93 | 0.370 |
Why?
|
| Female | 37 | 2024 | 30596 | 0.360 |
Why?
|
| Bacterial Translocation | 2 | 2007 | 8 | 0.360 |
Why?
|
| Genes, Bacterial | 6 | 2006 | 115 | 0.360 |
Why?
|
| Pneumococcal Infections | 3 | 2015 | 35 | 0.360 |
Why?
|
| Sequence Deletion | 3 | 2001 | 115 | 0.360 |
Why?
|
| Bacterial Vaccines | 6 | 1999 | 90 | 0.350 |
Why?
|
| Pregnancy | 13 | 2019 | 2319 | 0.350 |
Why?
|
| Vaccines, Conjugate | 7 | 2014 | 19 | 0.350 |
Why?
|
| Mass Media | 3 | 2020 | 30 | 0.350 |
Why?
|
| Molecular Sequence Data | 15 | 2013 | 1974 | 0.340 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2014 | 61 | 0.340 |
Why?
|
| Ebolavirus | 2 | 2022 | 34 | 0.330 |
Why?
|
| Cervix Uteri | 3 | 2007 | 56 | 0.330 |
Why?
|
| Serotyping | 11 | 2014 | 48 | 0.330 |
Why?
|
| Health Services Research | 1 | 2010 | 269 | 0.330 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 445 | 0.320 |
Why?
|
| Child | 8 | 2024 | 4225 | 0.310 |
Why?
|
| Infant, Newborn | 12 | 2022 | 1296 | 0.310 |
Why?
|
| Integrin alpha1beta1 | 1 | 2007 | 2 | 0.300 |
Why?
|
| Immunity, Maternally-Acquired | 5 | 2007 | 11 | 0.300 |
Why?
|
| Virulence Factors | 2 | 2008 | 80 | 0.290 |
Why?
|
| Streptococcus pneumoniae | 4 | 2015 | 59 | 0.280 |
Why?
|
| Zoonoses | 1 | 2006 | 7 | 0.280 |
Why?
|
| Phylogeny | 5 | 2021 | 322 | 0.280 |
Why?
|
| Registries | 1 | 2010 | 806 | 0.280 |
Why?
|
| Information Dissemination | 2 | 2006 | 113 | 0.280 |
Why?
|
| Immunoglobulin G | 5 | 2007 | 446 | 0.270 |
Why?
|
| Sepsis | 3 | 2013 | 274 | 0.270 |
Why?
|
| United States | 12 | 2024 | 7496 | 0.270 |
Why?
|
| Child, Preschool | 7 | 2024 | 1804 | 0.250 |
Why?
|
| Bacterial Capsules | 7 | 2008 | 21 | 0.250 |
Why?
|
| Public Health Surveillance | 2 | 2017 | 28 | 0.250 |
Why?
|
| Penicillin Resistance | 2 | 2015 | 8 | 0.250 |
Why?
|
| Mice | 21 | 2013 | 10140 | 0.250 |
Why?
|
| Data Collection | 4 | 2019 | 383 | 0.240 |
Why?
|
| Tandem Repeat Sequences | 2 | 2001 | 27 | 0.240 |
Why?
|
| Drosophila melanogaster | 1 | 2008 | 475 | 0.240 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2005 | 137 | 0.240 |
Why?
|
| Biosurveillance | 2 | 2014 | 3 | 0.230 |
Why?
|
| Gene Expression Regulation, Bacterial | 3 | 2013 | 145 | 0.230 |
Why?
|
| Adolescent | 9 | 2024 | 5857 | 0.220 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 57 | 0.220 |
Why?
|
| Animals, Newborn | 9 | 2008 | 228 | 0.220 |
Why?
|
| Rabbits | 11 | 2006 | 330 | 0.220 |
Why?
|
| Computer Systems | 2 | 2013 | 15 | 0.220 |
Why?
|
| Neglected Diseases | 2 | 2014 | 3 | 0.220 |
Why?
|
| Male | 16 | 2024 | 27241 | 0.220 |
Why?
|
| Algorithms | 3 | 2024 | 983 | 0.220 |
Why?
|
| Politics | 2 | 2020 | 30 | 0.220 |
Why?
|
| Bedding and Linens | 1 | 2023 | 4 | 0.220 |
Why?
|
| Carrier Proteins | 4 | 2005 | 713 | 0.210 |
Why?
|
| Penile Diseases | 1 | 2022 | 2 | 0.210 |
Why?
|
| Hepatitis E | 1 | 2022 | 1 | 0.210 |
Why?
|
| Hepatitis E virus | 1 | 2022 | 1 | 0.210 |
Why?
|
| Actins | 1 | 2004 | 254 | 0.210 |
Why?
|
| Skin Ulcer | 1 | 2022 | 12 | 0.210 |
Why?
|
| Quarantine | 1 | 2022 | 9 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2006 | 455 | 0.200 |
Why?
|
| Rectal Diseases | 1 | 2022 | 26 | 0.200 |
Why?
|
| Exanthema | 1 | 2022 | 27 | 0.200 |
Why?
|
| Viral Vaccines | 1 | 2002 | 49 | 0.200 |
Why?
|
| Protein Binding | 5 | 2009 | 1538 | 0.200 |
Why?
|
| Base Sequence | 9 | 2009 | 1314 | 0.200 |
Why?
|
| Cholera | 2 | 2011 | 11 | 0.200 |
Why?
|
| One Health | 1 | 2021 | 2 | 0.190 |
Why?
|
| Mutation | 5 | 2020 | 2411 | 0.190 |
Why?
|
| Rec A Recombinases | 1 | 2001 | 35 | 0.190 |
Why?
|
| Crowding | 1 | 2021 | 33 | 0.190 |
Why?
|
| Refugees | 1 | 2022 | 61 | 0.190 |
Why?
|
| Adult | 13 | 2024 | 15611 | 0.190 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 42 | 0.180 |
Why?
|
| Liver Abscess | 1 | 2000 | 17 | 0.180 |
Why?
|
| Mosaicism | 1 | 2000 | 25 | 0.180 |
Why?
|
| Salmonella enteritidis | 1 | 2020 | 4 | 0.180 |
Why?
|
| Forecasting | 2 | 2019 | 218 | 0.180 |
Why?
|
| Antigens, Viral | 1 | 2021 | 131 | 0.180 |
Why?
|
| Multigene Family | 1 | 2000 | 93 | 0.180 |
Why?
|
| Mumps virus | 1 | 2020 | 5 | 0.180 |
Why?
|
| Mumps | 1 | 2020 | 7 | 0.180 |
Why?
|
| Vagina | 2 | 2004 | 83 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 4 | 2014 | 694 | 0.180 |
Why?
|
| Seasons | 2 | 2024 | 138 | 0.180 |
Why?
|
| Cell Line | 5 | 2008 | 2009 | 0.180 |
Why?
|
| Genome, Bacterial | 3 | 2005 | 63 | 0.170 |
Why?
|
| RNA, Viral | 1 | 2021 | 265 | 0.170 |
Why?
|
| Schools, Medical | 1 | 2021 | 142 | 0.170 |
Why?
|
| Phagocytosis | 7 | 2008 | 249 | 0.170 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 36 | 0.170 |
Why?
|
| Risk Factors | 4 | 2023 | 4993 | 0.170 |
Why?
|
| Duodenoscopes | 1 | 2019 | 3 | 0.170 |
Why?
|
| Plants | 2 | 2012 | 42 | 0.160 |
Why?
|
| Listeriosis | 1 | 2019 | 30 | 0.160 |
Why?
|
| Equipment Contamination | 1 | 2019 | 32 | 0.160 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 26 | 0.160 |
Why?
|
| Pain | 1 | 2022 | 404 | 0.160 |
Why?
|
| Monkeypox virus | 3 | 2023 | 7 | 0.160 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 44 | 0.160 |
Why?
|
| Amino Acid Sequence | 7 | 2007 | 1577 | 0.160 |
Why?
|
| Liver Transplantation | 1 | 2020 | 171 | 0.160 |
Why?
|
| Binding Sites | 4 | 2009 | 869 | 0.150 |
Why?
|
| Streptococcus | 1 | 1997 | 17 | 0.150 |
Why?
|
| Machine Learning | 1 | 2019 | 131 | 0.150 |
Why?
|
| Young Adult | 5 | 2024 | 4259 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2019 | 309 | 0.150 |
Why?
|
| Epitopes | 3 | 1996 | 298 | 0.140 |
Why?
|
| Immunization, Passive | 4 | 1999 | 100 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2020 | 251 | 0.140 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 4 | 0.130 |
Why?
|
| Infant | 5 | 2021 | 1506 | 0.130 |
Why?
|
| Cloning, Molecular | 5 | 2001 | 381 | 0.130 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 306 | 0.130 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2016 | 24 | 0.130 |
Why?
|
| Mass Screening | 1 | 2021 | 636 | 0.130 |
Why?
|
| Uveitis | 1 | 2016 | 29 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 3 | 2007 | 660 | 0.130 |
Why?
|
| Bacterial Adhesion | 2 | 2007 | 58 | 0.130 |
Why?
|
| Microscopy, Confocal | 2 | 2007 | 218 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2020 | 170 | 0.120 |
Why?
|
| Bacteremia | 4 | 2015 | 92 | 0.120 |
Why?
|
| Confidentiality | 1 | 2015 | 52 | 0.120 |
Why?
|
| Leishmaniasis | 1 | 2014 | 10 | 0.120 |
Why?
|
| Virulence | 6 | 2013 | 187 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 70 | 0.120 |
Why?
|
| Travel | 2 | 2011 | 31 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2014 | 20 | 0.120 |
Why?
|
| Critical Care | 2 | 2020 | 401 | 0.120 |
Why?
|
| Comorbidity | 2 | 2014 | 1095 | 0.120 |
Why?
|
| Logistic Models | 2 | 2014 | 1268 | 0.110 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 788 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2014 | 849 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2018 | 3058 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 4 | 2020 | 389 | 0.110 |
Why?
|
| Fimbriae, Bacterial | 1 | 2013 | 19 | 0.110 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2013 | 10 | 0.110 |
Why?
|
| Social Class | 1 | 2013 | 123 | 0.110 |
Why?
|
| Age Distribution | 1 | 2013 | 265 | 0.110 |
Why?
|
| Sputum | 1 | 2012 | 36 | 0.110 |
Why?
|
| Boston | 2 | 2020 | 330 | 0.110 |
Why?
|
| Coronavirus | 1 | 2012 | 12 | 0.110 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2012 | 24 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 3 | 2001 | 492 | 0.110 |
Why?
|
| Government | 1 | 2012 | 7 | 0.100 |
Why?
|
| Disease Notification | 1 | 2012 | 6 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 1089 | 0.100 |
Why?
|
| Private Sector | 1 | 2012 | 14 | 0.100 |
Why?
|
| Contact Tracing | 2 | 2022 | 14 | 0.100 |
Why?
|
| Cell Wall | 1 | 2013 | 113 | 0.100 |
Why?
|
| Middle Aged | 6 | 2024 | 16201 | 0.100 |
Why?
|
| Ecosystem | 1 | 2012 | 39 | 0.100 |
Why?
|
| Fungi | 1 | 2012 | 50 | 0.100 |
Why?
|
| Mycoses | 1 | 2012 | 41 | 0.100 |
Why?
|
| Vibrio cholerae | 1 | 2011 | 11 | 0.100 |
Why?
|
| Cell Line, Tumor | 2 | 2007 | 1345 | 0.100 |
Why?
|
| Communication | 1 | 2016 | 530 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2004 | 667 | 0.090 |
Why?
|
| Molecular Epidemiology | 2 | 2021 | 26 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 2025 | 0.090 |
Why?
|
| Diarrhea | 1 | 2011 | 73 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2012 | 257 | 0.090 |
Why?
|
| Amino Acid Motifs | 2 | 2009 | 151 | 0.090 |
Why?
|
| Length of Stay | 1 | 2014 | 775 | 0.090 |
Why?
|
| Immune Sera | 4 | 1999 | 35 | 0.090 |
Why?
|
| Incidence | 3 | 2015 | 1235 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 961 | 0.090 |
Why?
|
| Schools | 2 | 2022 | 156 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 3 | 1992 | 866 | 0.090 |
Why?
|
| Age Factors | 1 | 2014 | 1530 | 0.090 |
Why?
|
| Asthma | 1 | 2014 | 414 | 0.090 |
Why?
|
| Immunoglobulin M | 2 | 2007 | 112 | 0.090 |
Why?
|
| Recombinant Proteins | 4 | 2008 | 684 | 0.090 |
Why?
|
| Immunoglobulin A | 3 | 2007 | 93 | 0.090 |
Why?
|
| Central America | 1 | 2009 | 2 | 0.080 |
Why?
|
| Mexico | 1 | 2009 | 42 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2007 | 252 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2000 | 358 | 0.080 |
Why?
|
| Blotting, Western | 4 | 2001 | 590 | 0.080 |
Why?
|
| Species Specificity | 2 | 2006 | 331 | 0.080 |
Why?
|
| Molecular Weight | 2 | 2000 | 187 | 0.080 |
Why?
|
| Crystallography, X-Ray | 2 | 2007 | 415 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2008 | 70 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2008 | 158 | 0.080 |
Why?
|
| Streptococcus pyogenes | 2 | 2005 | 27 | 0.080 |
Why?
|
| Animals, Outbred Strains | 2 | 2007 | 8 | 0.080 |
Why?
|
| Spleen | 2 | 2001 | 484 | 0.070 |
Why?
|
| Bacterial Typing Techniques | 1 | 2007 | 12 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 198 | 0.070 |
Why?
|
| Genital Diseases, Female | 1 | 2007 | 16 | 0.070 |
Why?
|
| Aged | 5 | 2024 | 13273 | 0.070 |
Why?
|
| DNA, Bacterial | 4 | 2006 | 251 | 0.070 |
Why?
|
| Time Factors | 3 | 2016 | 3560 | 0.070 |
Why?
|
| Subcellular Fractions | 2 | 2004 | 66 | 0.070 |
Why?
|
| Cross Reactions | 2 | 1997 | 123 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2006 | 71 | 0.070 |
Why?
|
| Point Mutation | 1 | 2007 | 162 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 73 | 0.070 |
Why?
|
| Genomics | 1 | 2009 | 311 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 250 | 0.070 |
Why?
|
| DNA Primers | 2 | 1996 | 293 | 0.060 |
Why?
|
| Conserved Sequence | 2 | 2009 | 169 | 0.060 |
Why?
|
| Cross Infection | 1 | 2007 | 142 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 196 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2024 | 5959 | 0.060 |
Why?
|
| RNA Interference | 1 | 2008 | 584 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2005 | 47 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 1437 | 0.060 |
Why?
|
| Chlorates | 1 | 2004 | 2 | 0.060 |
Why?
|
| Digitonin | 1 | 2004 | 4 | 0.060 |
Why?
|
| Cytochalasin D | 1 | 2004 | 20 | 0.060 |
Why?
|
| Polysaccharide-Lyases | 1 | 2004 | 3 | 0.060 |
Why?
|
| Cytotoxins | 1 | 2004 | 12 | 0.060 |
Why?
|
| Immunoassay | 1 | 2004 | 52 | 0.060 |
Why?
|
| Sequence Alignment | 2 | 2005 | 289 | 0.060 |
Why?
|
| World Health Organization | 2 | 2016 | 30 | 0.060 |
Why?
|
| Codon, Initiator | 1 | 2003 | 11 | 0.060 |
Why?
|
| Lung | 1 | 2008 | 818 | 0.060 |
Why?
|
| Hospitals | 1 | 2007 | 375 | 0.060 |
Why?
|
| Transcription Initiation Site | 1 | 2003 | 48 | 0.060 |
Why?
|
| Bacterial Toxins | 1 | 2004 | 59 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2007 | 1109 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2003 | 151 | 0.060 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 128 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2005 | 350 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2024 | 110 | 0.050 |
Why?
|
| Heparin | 1 | 2004 | 113 | 0.050 |
Why?
|
| Cytosol | 1 | 2004 | 167 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 2856 | 0.050 |
Why?
|
| Trifluridine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Isoindoles | 1 | 2022 | 3 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2003 | 242 | 0.050 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2002 | 5 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2004 | 269 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 173 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2002 | 20 | 0.050 |
Why?
|
| Protein Transport | 1 | 2004 | 393 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 47 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 12 | 0.050 |
Why?
|
| Anus Diseases | 1 | 2022 | 5 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2022 | 17 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 521 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 107 | 0.050 |
Why?
|
| Cell Polarity | 1 | 2002 | 110 | 0.050 |
Why?
|
| Kinetics | 1 | 2004 | 727 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 351 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 805 | 0.050 |
Why?
|
| Microfluidics | 1 | 2022 | 21 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 111 | 0.050 |
Why?
|
| Genetic Variation | 3 | 2007 | 362 | 0.050 |
Why?
|
| Neonatal Screening | 1 | 2022 | 94 | 0.050 |
Why?
|
| Rectum | 1 | 2022 | 82 | 0.050 |
Why?
|
| Masks | 1 | 2021 | 20 | 0.050 |
Why?
|
| Dominican Republic | 2 | 2011 | 23 | 0.050 |
Why?
|
| Biological Transport | 1 | 2002 | 288 | 0.050 |
Why?
|
| Models, Animal | 1 | 2002 | 217 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 29 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2004 | 489 | 0.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2005 | 71 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 15 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2009 | 1448 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 95 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2021 | 57 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 194 | 0.050 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2000 | 7 | 0.050 |
Why?
|
| Suppuration | 1 | 2000 | 11 | 0.050 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 1125 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2000 | 81 | 0.040 |
Why?
|
| Authoritarianism | 1 | 2020 | 1 | 0.040 |
Why?
|
| Cytokines | 1 | 2004 | 900 | 0.040 |
Why?
|
| Candida | 1 | 2020 | 34 | 0.040 |
Why?
|
| Prejudice | 1 | 2020 | 61 | 0.040 |
Why?
|
| Tetanus Toxoid | 1 | 1999 | 15 | 0.040 |
Why?
|
| Drainage | 1 | 2000 | 143 | 0.040 |
Why?
|
| Temperature | 1 | 2021 | 299 | 0.040 |
Why?
|
| Community Health Services | 1 | 2021 | 130 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 116 | 0.040 |
Why?
|
| Colistin | 1 | 2019 | 7 | 0.040 |
Why?
|
| Enterococcus faecium | 1 | 1999 | 6 | 0.040 |
Why?
|
| Enterococcus faecalis | 1 | 1999 | 9 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 2019 | 33 | 0.040 |
Why?
|
| Vancomycin | 1 | 1999 | 32 | 0.040 |
Why?
|
| Gene Expression | 2 | 2005 | 805 | 0.040 |
Why?
|
| Food Handling | 1 | 2019 | 45 | 0.040 |
Why?
|
| Students | 1 | 2021 | 208 | 0.040 |
Why?
|
| Lethal Dose 50 | 1 | 1998 | 12 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2000 | 449 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 1997 | 12 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 252 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 161 | 0.040 |
Why?
|
| Genotype | 1 | 2020 | 638 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2020 | 259 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2017 | 21 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 5062 | 0.040 |
Why?
|
| Software Design | 1 | 2017 | 28 | 0.040 |
Why?
|
| Information Systems | 1 | 2017 | 30 | 0.040 |
Why?
|
| Climate Change | 1 | 2017 | 16 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 417 | 0.040 |
Why?
|
| Fetal Blood | 2 | 2007 | 70 | 0.040 |
Why?
|
| Antibody Specificity | 2 | 2007 | 99 | 0.040 |
Why?
|
| Immunochemistry | 1 | 1997 | 11 | 0.040 |
Why?
|
| Curriculum | 1 | 2021 | 542 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 104 | 0.030 |
Why?
|
| Trypsin | 1 | 1996 | 40 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 1996 | 18 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 907 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 201 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1997 | 68 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2017 | 162 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 142 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 340 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2017 | 228 | 0.030 |
Why?
|
| Liberia | 1 | 2016 | 8 | 0.030 |
Why?
|
| Pakistan | 1 | 2016 | 14 | 0.030 |
Why?
|
| Endopeptidases | 2 | 1999 | 65 | 0.030 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2015 | 1 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 371 | 0.030 |
Why?
|
| Epidemiology | 1 | 2015 | 7 | 0.030 |
Why?
|
| Penicillins | 1 | 2014 | 28 | 0.030 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2014 | 12 | 0.030 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2014 | 11 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 306 | 0.030 |
Why?
|
| Escherichia coli | 2 | 1997 | 671 | 0.030 |
Why?
|
| France | 1 | 2014 | 11 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2007 | 1046 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 52 | 0.030 |
Why?
|
| Social Media | 1 | 2016 | 109 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 197 | 0.030 |
Why?
|
| Heat-Shock Response | 1 | 2013 | 34 | 0.030 |
Why?
|
| Middle East | 1 | 2012 | 6 | 0.030 |
Why?
|
| Opsonin Proteins | 2 | 2005 | 31 | 0.030 |
Why?
|
| Extinction, Biological | 1 | 2012 | 6 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 85 | 0.030 |
Why?
|
| Vibrio cholerae O1 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2015 | 247 | 0.020 |
Why?
|
| Haiti | 1 | 2011 | 8 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 1991 | 27 | 0.020 |
Why?
|
| Food Supply | 1 | 2012 | 73 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 272 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1991 | 189 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2011 | 52 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1997 | 834 | 0.020 |
Why?
|
| Feces | 1 | 2011 | 93 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 84 | 0.020 |
Why?
|
| Poverty | 1 | 2012 | 294 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1020 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 657 | 0.020 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1989 | 8 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 50 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1991 | 879 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 71 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 900 | 0.020 |
Why?
|
| Fetus | 1 | 2008 | 98 | 0.020 |
Why?
|
| Phenotype | 1 | 1991 | 1149 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2007 | 23 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2008 | 423 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 1264 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 1989 | 534 | 0.020 |
Why?
|
| Immunodiffusion | 1 | 2006 | 4 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 1991 | 313 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 652 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2007 | 297 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2005 | 39 | 0.020 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2005 | 11 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2565 | 0.020 |
Why?
|
| Crystallization | 1 | 2005 | 97 | 0.020 |
Why?
|
| Rats | 1 | 2008 | 1884 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2004 | 84 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 5115 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 142 | 0.010 |
Why?
|
| Computational Biology | 1 | 2005 | 321 | 0.010 |
Why?
|
| Neutrophils | 1 | 2005 | 348 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2002 | 106 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 573 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 288 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 2086 | 0.010 |
Why?
|
| Peritoneum | 1 | 1999 | 25 | 0.010 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 1999 | 3 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1999 | 42 | 0.010 |
Why?
|
| Uterus | 1 | 1999 | 40 | 0.010 |
Why?
|
| Biomass | 1 | 1999 | 27 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1999 | 31 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1999 | 96 | 0.010 |
Why?
|
| Random Allocation | 1 | 1999 | 198 | 0.010 |
Why?
|
| Hemolysin Proteins | 1 | 1999 | 45 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1999 | 42 | 0.010 |
Why?
|
| Gestational Age | 1 | 1999 | 178 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1997 | 46 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 1997 | 57 | 0.010 |
Why?
|
| Spain | 1 | 1993 | 27 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1993 | 56 | 0.010 |
Why?
|
| TATA Box | 1 | 1992 | 12 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 54 | 0.010 |
Why?
|
| Protein Sorting Signals | 1 | 1992 | 57 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 180 | 0.010 |
Why?
|
| Plasmids | 1 | 1991 | 272 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 1991 | 127 | 0.010 |
Why?
|
| Mycobacterium avium Complex | 1 | 1989 | 3 | 0.010 |
Why?
|
| Prevalence | 1 | 1993 | 1276 | 0.010 |
Why?
|
| Toxoplasma | 1 | 1989 | 30 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 137 | 0.000 |
Why?
|
| Monocytes | 1 | 1989 | 349 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1989 | 227 | 0.000 |
Why?
|
| Macrophages | 1 | 1989 | 992 | 0.000 |
Why?
|